Back to Search
NANCY ZINNER, PH.D.
PH.D.
Clinical Psychologist
NPI: 1801837158Individual
Specialties, Licenses & Credentials
Clinical PsychologistPrimary
Psychologist — Clinical
Code: 103TC0700X
PSY13072(CA)
Research & Publications (20)
Darifenacin treatment for overactive bladder in patients who expressed dissatisfaction with prior extended-release antimuscarinic therapy.
PMID 18811599·Int J Clin Pract·2008
4-observational
Impact of solifenacin on resource utilization, work productivity and health utility in overactive bladder patients switching from tolterodine ER.
PMID 18423103·Curr Med Res Opin·2008
3-trial
Darifenacin: a muscarinic M3-selective receptor antagonist for the treatment of overactive bladder.
PMID 17309345·Expert Opin Pharmacother·2007
6-review
Do food and dose timing affect the efficacy of sildenafil? A randomized placebo-controlled study.
PMID 17233779·J Sex Med·2007
2-rct
Trospium chloride: an anticholinergic quaternary ammonium compound for the treatment of overactive bladder.
PMID 16013990·Expert Opin Pharmacother·2005
6-review
Similar frequency of testosterone surge after repeat injections of goserelin (Zoladex) 3.6 mg and 10.8 mg: results of a randomized open-label trial.
PMID 15596193·Urology·2004
3-trial
Pharmacotherapy for stress urinary incontinence : present and future options.
PMID 15233589·Drugs·2004
6-review
Duloxetine: a serotonin-noradrenaline re-uptake inhibitor for the treatment of stress urinary incontinence.
PMID 12943499·Expert Opin Investig Drugs·2003
6-review
Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients.
PMID 12028164·J Am Geriatr Soc·2002
3-trial
Comment on "Coexistence of BCS- and BEC-like pair structures in halo nuclei".
PMID 18999795·Phys Rev Lett·2008
8-other
Efficacy, tolerability and safety of darifenacin, an M(3) selective receptor antagonist: an investigation of warning time in patients with OAB.
PMID 16409440·Int J Clin Pract·2006
4-observational
Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder.
PMID 16096831·World J Urol·2005
2-rct
The overactive bladder-symptom composite score: a composite symptom score of toilet voids, urgency severity and urge urinary incontinence in patients with overactive bladder.
PMID 15821526·J Urol·2005
3-trial
Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial.
PMID 15126811·J Urol·2004
3-trial
Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
PMID 19014833·Clin Ther·2008
3-trial
Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study.
PMID 18342185·Urology·2008
3-trial
Effects of oxybutynin transdermal system on health-related quality of life and safety in men with overactive bladder and prostate conditions.
PMID 17983434·Int J Clin Pract·2008
4-observational
Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial.
PMID 17632131·J Urol·2007
3-trial
Managing the progression of lower urinary tract symptoms/benign prostatic hyperplasia: therapeutic options for the man at risk.
PMID 17617135·BJU Int·2007
6-review
Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study.
PMID 17187655·BJU Int·2007
4-observational
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 24445 HAWTHORNE BLVD, SUITE 202
TORRANCE, CA 90505 - Phone
- (310) 375-7139
Quick Facts
- NPI
- 1801837158
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile